Trump Taking Credit for Decline in Drug Prices, but Reason for the Drop Is Complex

President Donald Trump has been claiming credit for a decline in U.S. prescription drug prices, which recently fell by 0.8% in July and a yearly 3.1% decrease since 1963. The White House attributes the drop to his favored nation (MFN) deals with pharmaceutical companies and the TrumpRx website. However, drug pricing experts say the situation is more complex, with other factors like Medicare negotiation rights from the Biden administration and competitive market forces potentially playing more significant roles in the price reductions.

Experts note that while competition from generic and biosimilar drugs has pressured down the cost of expensive brand-name and biologic medications, details about the impact of the MFN deals with drug companies remain unclear due to the secrecy surrounding those agreements. The Trump administration has promised more savings from these deals in the future, but has not yet been implemented on a federal level.

Additionally, the Labor Department's price index does not reflect the actual amount consumers pay for drugs, as it measures what pharmacies are paid by insurers. This makes it challenging to gauge the full impact of price reductions on individual patients. Despite the drop in prices, many consumers still face high drug costs and rising overall health expenses due to factors like higher insurance premiums and out-of-pocket costs.